Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals — Stella

Recruiting

Back to HIV Infections trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Brazil

Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro

Key details

Phase

Post-approval study

Sponsor

Oswaldo Cruz Foundation

Enrollment target

~400 participants

Started

May 2017

Primary completion

December 2018

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 59 Years

Last updated July 2018

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov